AAN 2022 | An overview of research into treatment options for cluster headaches
Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, explains that there is still a lack of new treatment targets for cluster headaches. Nevertheless, Dr Ailani points out interesting updates in the field, including a study on ketamine nasal spray for treating cluster headache (NCT04179266), as well as a familial study to determine the genetics of cluster headaches. New therapies for cluster headache have been frustrating with some monoclonal antibodies showing efficacy while others not. Currently, there is an ongoing clinical trial (NCT04688775) on intravenous eptinezumab for cluster headache. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Consulting (Honoraria): Abbvie, Amgen, Aeon (Data monitoring board), Axsome, Biohaven, BioDeliveryScientificInternational, Eli-Lilly, GlaxoSmithKline, Lundbeck, Impel, Neurolief, Neso, Satsuma, Theranica, Teva
Clinical Trials (Grant to institution): Abbvie, Biohaven, Eli-Lilly, Satsuma, Zosano
Stock Options: CtrlM (less than 2%)
Editorial Boards/Steering Committee: Medscape, NeurologyLive, Current Pain and Headache (Editor, Unusual Headache Syndromes), SELF magazine (medical editor)
